{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-25-000127","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.679609+00:00","generated_at":"2026-05-17T00:48:13.835895+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Exelixis Q3 revenues $597.8M, EPS $0.69; announces $750M stock buyback by 2026","bullets":["Total revenues $597.8M (+10.8% YoY); cabozantinib US net product rev $542.9M (+13.5% YoY).","GAAP diluted EPS $0.69 (vs $0.40); Non-GAAP diluted EPS $0.78 (vs $0.47).","Board authorized $750M stock repurchase program through Dec 31, 2026.","Restructuring charges $19.8M related to corporate reorganization; plan to close King of Prussia office.","Zanzalintinib NDA submission planned before year-end based on positive STELLAR-303 colorectal cancer data."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-25-000127","json":"https://secwatch.observer/filing/0000939767-25-000127.json","markdown":"https://secwatch.observer/filing/0000939767-25-000127.md","text":"https://secwatch.observer/filing/0000939767-25-000127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/0000939767-25-000127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/exel-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:48:13.835895+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}